Biopharma News

Oct 01, 2018
By BioPharm International Editors
Kangstem Biotech has selected Orgenesis subsidiary, MaSTherCell, as its contract manufacturing partner for the European clinical trial of Furestem-AD.
Oct 01, 2018
By BioPharm International Editors
The companies partnered to build a 500-L single-use pilot-scale plant for biologics production.
Sep 27, 2018
By BioPharm International Editors
The company plans to lay off approximately 400 employees to support the restructuring of its R&D organization.
Sep 27, 2018
By BioPharm International Editors
The sterile-manufacturing contract development manufacturing organization is approved by FDA for viral vector manufacturing fill/finish processing at its biologics facility in Scotland, UK.
Sep 27, 2018
By BioPharm International Editors
The company’s biosimiliar to Amgen’s Neulasta (pegfilgrastim) received a positive opinion for marketing authorization from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).
Sep 24, 2018
By BioPharm International Editors
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended 13 new medicines for approval, including three orphan drug candidates.
Sep 21, 2018
By BioPharm International Editors
The European Medicines Agency has recommended Luxturna (voretigene neparvovec) as the first treatment option for hereditary retinal dystrophy with mutations of the RPE65 gene.
Sep 20, 2018
By BioPharm International Editors
The biopharmaceutical company will invest approximately $800 million to expand facilities and manufacturing capacity at its campus in Rensselaer County, NY.
Sep 20, 2018
By BioPharm International Editors
BeiGene is set to build late-stage clinical and commercial production capacity for cancer monoclonal antibodies with GE Healthcare’s KUBio, the prefabricated biopharma facility based on single-use technologies.
Sep 20, 2018
By BioPharm International Editors
The agency will review Praluent (alirocumab) Injection, a PCSK9 inhibitor, as a possible treatment of cardiovascular events.
native1_300x100
lorem ipsum